Cyclic derivatives as modulators of chemokine receptor activity
The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma, processes for preparing and intermediates thereof.
1. A compound of formula (I):
or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein:
ring B is a cyclohexyl group, ring B being substituted with 0–2 R 5 ;
X is selected from O or S;
Z is —NR 9 —;
wherein neither Z nor R 13 are connected to a carbon atom labeled (b);
bond (a) is a single bond;
E is selected from —S(O) p CHR e —, —CHR e NR e —, —C(O)—NR e —, —NR e C(O)NR e —, —SO 2 —NR e —, and —NR e SO 2 NR e —;
R e is independently selected from H and C 1-3 alkyl;
R 1 is selected from a C 6-10 aryl group substituted with 0–5 R 6 ;
R 2 is selected from a 5–10 membered heteroaryl system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–3 R 7 ;
R 5 , at each occurrence, is independently selected from H, ═O, C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CRR) r OH, (CRR) r SH, (CRR) r OR 5d , ′(CRR) r SR 5d , (CRR) r NR 5a R 5a , (CRR) r N(→O)R 5a R 5a , N 3 , (CRR) r C(O)OH, (CRR) r C(O)R 5b , (CRR) r C(O)NR 5a R 5a , (CRR) r NR 5a C(O)R 5b , (CRR) r OC(O)NR 5a R 5a , (CRR) r NR 5a C(O)OR 5d , (CRR) r NR 5a C(O)NR 5a R 5a , (CRR) r NR 5a C(O)H, (CRR) r C(O)OR 5d , (CRR) r OC(O)R 5b , (CRR) r S(O) p R 5b , (CRR) r S(O) 2 NR 5a R 5a , (CRR) r NR 5a S(O) 2 R 5b , (CRR) r NR 5a S(O) 2 NR 5a R 5a , C 1-6 haloalkyl, a (CRR) r —C 3-10 carbocyclic residue substituted with 0–3 R 5c , and a (CRR) r -5–10 membered heterocyclic system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–2 R 5c ;
R 5a , at each occurrence, is independently selected from H, methyl substituted with 0–1 R 5g , C 2-6 alkyl substituted with 0–2 R 5e , C 3-8 alkenyl substituted with 0–2 R 5e , C 3-8 alkynyl substituted with 0–2 R 5e , a (CH 2 ) r —C 3-10 carbocyclic residue substituted with 0–5 R 5e , and a (CH 2 ) r -5–10 membered heterocyclic system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–3 R 5e ;
R 5b , at each occurrence, is selected from C 1-6 alkyl substituted with 0–3 R 5e , C 3-8 alkenyl substituted with 0–2 R 5e , C 3-8 alkynyl substituted with 0–2 R 5e , a (CH 2 ) r C 3-6 carbocyclic residue substituted with 0–2 R 5e , and a (CH 2 ) r -5–6 membered heterocyclic system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–3 R 5e ;
R 5c , at each occurrence, is selected from C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, Cl, Br, I, F, (CF 2 ) r CF 3 , NO 2 , CN, (CH 2 ) r NR 5f R 5f , (CH 2 ) r OH, (CH 2 ) r OC 1-4 alkyl, (CH 2 ) r SC 1-4 alkyl, (CH 2 ) r C(O)OH, (CH 2 ) r C(O)R 5b , (CH 2 ) r C(O)NR 5f R 5f , (CH 2 )rOC(O)NR 5f R 5f , (CH 2 ) r NR 5f C(O)R 5b , (CH 2 ) r C(O)OC 1-4 alkyl, (CH 2 ) r NR 5f C(O)OC 1-4 alkyl, (CH 2 ) r OC(O)R 5b , (CH 2 ) r C(═NR 5f )NR 5f R 5f , (CH 2 ) r S(O) p R 5b , (CH 2 ) r NHC(═NR 5f )NR 5f R 5f , (CH 2 ) r S(O) 2 NR 5f R 5f , (CH 2 ) r NR 5f S(O) 2 R 5b , and (CH 2 ) r phenyl substituted with 0–3 R 5e ;
R 5d , at each occurrence, is selected from methyl, CF 3 , C 2-6 alkyl substituted with 0–2 R 5e , C 3-8 alkenyl substituted with 0–2 R 5e , C 3-8 alkynyl substituted with 0–2 R 5e , and a C 3-10 carbocyclic residue substituted with 0–3 R 5e ;
R 5e , at each occurrence, is selected from C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 3-6 cycloalkyl, Cl, F, Br, I, CN, NO 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC 1-5 alkyl, OH, SH, (CH 2 ) r SC 1-5 alkyl, (CH 2 ) r NR 5f R 5f , and (CH 2 ) r phenyl;
R 5f , at each occurrence, is selected from H, C 1-6 alkyl, and C 3-6 cycloalkyl;
R 5g is independently selected from —C(O)R 5b , —C(O)OR 5d , —C(O)NR 5f R 5f , —CN, and (CH 2 ) r phenyl;
R, at each occurrence, is selected from H, C 1-6 alkyl substituted with R 5e , C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, and (CH 2 ) r phenyl substituted with R 5e ;
R 6 , at each occurrence, is selected from C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, Cl, Br, I, F, NO 2 , CN, (CR′R′) r NR 6a R 6a , (CR′R′) r OH, (CR′R′) r O(CR′R′) r R 6d , (CR′R′) r SH, (CR′R′) r C(O)H, (CR′R′) r S(CR′R′) r R 6d , (CR′R′) r SC(O)(CR′R′) r R 6b , (CR′R′) r C(O)OH, (CR′R′) r C(O)(CR′R′) r R 6b , (CR′R′) r NR 6a R 6a , (CR′R′) r C(O)NR 6a R 6a , (CR′R′) r NR 6f C(O)(CR′R′) r R 6b , (CR′R′) r C(O)O(CR′R′) r R 6d , (CR′R′) r OC(O)(CR′R′) r R 6b , (CR′R′) r OC(O)NR 6a (CR′R′) r R 6d , (CR′R′) r NR 6a C(O)NR 6a (CR′R′) r R 6d , (CR′R′) r NR 6a C(S)NR 6a (CR′R′) r R 6d , (CR′R′) r NR 6f C(O)O(CR′R′) r R 6b , (CR′R′) r C(═NR 6f )NR 6a R 6a , (CR′R′) r NHC(═NR 6f )NR 6f R 6f , (CR′R′) r S(O) p (CR′R′) r R 6b , (CR′R′) r S(O) 2 NR 6a R 6a , (CR′R′) r NR 6f S(O) 2 NR 6a R 6a , (CR′R′) r NR 6f S(O) 2 (CR′R′) r R 6b , C 1-6 haloalkyl, C 2-8 alkenyl substituted with 0–3 R′, C 2-8 alkynyl substituted with 0–3 R′, (CR′R′) r phenyl substituted with 0–3 R 6e , and a (CH 2 ) r -5–6 membered heterocyclic system containing 1–2 heteroatoms selected from N, O, and S, substituted with 0–2 R 6e ;
alternatively, two R 6 on adjacent atoms on R 1 may join to form a cyclic acetal;
R 6a , at each occurrence, is selected from H, methyl substituted with 0–1 R 6g , C 2-6 alkyl substituted with 0–2 R 6e , C 3-8 alkenyl substituted with 0–2 R 6e , C 3-8 alkynyl substituted with 0–2 R 6e , a (CH 2 ) r —C 3-10 carbocyclic residue substituted with 0–5 R 6e , and a (CH 2 ) r -5–10 membered heterocyclic system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–2 R 6e ;
R 6b , at each occurrence, is selected from H, C 1-6 alkyl substituted with 0–2 R 6e , C 3-8 alkenyl substituted with 0–2 R 6e , C 3-8 alkynyl substituted with 0–2 R 6e , a (CH 2 ) r C 3-6 carbocyclic residue substituted with 0–3 R 6e , and a (CH 2 ) r -5–6 membered heterocyclic system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–2 R 6e ;
R 6d , at each occurrence, is selected from C 3-8 alkenyl substituted with 0–2 R 6e , C 3-8 alkynyl substituted with 0–2 R 6e , methyl, CF 3 , C 2-6 alkyl substituted with 0–3 R 6e , C 2-4 haloalkyl, a (CH 2 ) r —C 3-10 carbocyclic residue substituted with 0–3 R 6e , and a (CH 2 ) r -5–6 membered heterocyclic system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–3 R 6e ;
R 6e , at each occurrence, is selected from C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, Cl, F, Br, I, CN, NO 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC 1-5 alkyl, OH, SH, (CH 2 ) r SC 1-5 alkyl, (CH 2 ) r NR 6f R 6f , and (CH 2 ) r phenyl;
R 6f , at each occurrence, is selected from H, C 1–5 alkyl, and C 3–6 cycloalkyl, and phenyl;
R 6g is independently selected from —C(O)R 6b , —C(O)OR 6d , —C(O)NR 6f R 6f , and (CH 2 ) r phenyl;
R 7 , at each occurrence, is selected from C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, Cl, Br, I, F, NO 2 , CN, (CR′R′) r NR 7a R 7a , (CR′R′) r OH, (CR′R′) r O(CR′R′) r R 7d , (CR′R′) r SH, (CR′R′) r C(O)H, (CR′R′) r S(CR′R′) r R 7d , (CR′R′) r C(O)OH, (CR′R′) r C(O)(CR′R′) r R 7b , (CR′R′) r C(O)NR 7a R 7a , (CR′R′) r NR 7f C(O)(CR′R′) r R 7b , (CR′R′) r C(O)O(CR′R′) r R 7d , (CR′R′) r OC(O)(CR′R′) r R 7b , (CR′R′) r OC(O)NR 7a (CR′R′) r R 7a , (CR′R′) r NR 7a C(O)NR 7a (CR′R′) r R 7a , (CR′R′) r NR 7f C(O)O(CR′R′) r R 7d , (CR′R′) r C(═NR 7f )NR 7a R 7a , (CR′R′) r NHC(═NR 7f )NR 7f R 7f , (CR′R′) r S(O) p (CR′R′) r R 7b , (CR′R′) r S(O) 2 NR 7a R 7a , (CR′R′) r NR 7a S(O) 2 NR 7a R 7a , (CR′R′) r NR 7f S(O) 2 (CR′R′) r R 7b , C 1–6 haloalkyl, C 2-8 alkenyl substituted with 0–3 R′, C 2-8 alkynyl substituted with 0–3 R′, (CR′R′) r C 3-10 carbocyclic residue and (CR′R′) r phenyl substituted with 0–3 R 7e ;
alternatively, two R 7 on adjacent atoms on R 2 may join to form a cyclic acetal;
R 7a , at each occurrence, is independently selected from H, methyl substituted with 0–1 R 7g , C 2-6 alkyl substituted with 0–2 R 7e , C 3-8 alkenyl substituted with 0–2 R 7e , C 3-8 alkynyl substituted with 0–2 R 7e , a (CH 2 ) r —C 3-10 carbocyclic residue substituted with 0–5 R 7e , and a (CH 2 ) r -5–10 membered heterocyclic system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–2 R 7e ;
R 7b , at each occurrence, is selected from C 1-6 alkyl substituted with 0–2 R 7e , C 3-8 alkenyl substituted with 0–2 R 7e , C 3-8 alkynyl substituted with 0–2 R 7e , a (CH 2 ) r C 3-6 carbocyclic residue substituted with 0–3 R 7e , and a (CH 2 ) r -5–6 membered heterocyclic system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–2 R 7e ;
R 7d , at each occurrence, is selected from C 3-8 alkenyl substituted with 0–2 R 7e , C 3-8 alkynyl substituted with 0–2 R 7e , methyl, CF 3 , C 2-4 haloalkyl, C 2-6 alkyl substituted with 0–3 R 7e , a (CH 2 ) r C 3-10 carbocyclic residue substituted with 0–3 R 7e , and a (CH 2 ) r -5–6 membered heterocyclic system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–3 R 7e ;
R 7e , at each occurrence, is selected from C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, Cl, F, Br, I, CN, NO 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC 1-5 alkyl, OH, SH, C(O)OC 1-5 alkyl, (CH 2 ) r SC 1-5 alkyl, (CH 2 ) r NR 7f R 7f , and (CH 2 ) r phenyl;
R 7f , at each occurrence, is selected from H, C 1-5 alkyl, and C 3-6 cycloalkyl, and phenyl;
R 7g is independently selected from —C(O)R 7b , —C(O)OR 7d , —C(O)NR 7f R 7f , and (CH 2 ) r phenyl;
R′, at each occurrence, is selected from H, C 1-6 alkyl substituted with R 6e , C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, and (CH 2 ) r phenyl substituted with R 6e ;
R 9 is selected from H, C 1-4 alkyl, C 3-4 cycloalkyl, —C(O)H, and —C(O)—C 1-4 alkyl;
R 10 is independently selected from H, and C 1-4 alkyl substituted with 0–1 R 10b , alternatively, two R 10 form ═O;
R 10b , at each occurrence, is independently selected from —OH, —SH, —NR 10c R 10c , —C(O)NR 10c R 10C , and —NHC(O)R 10c ;
R 10c is selected from H, C 1-4 alkyl and C 3-6 cycloalkyl;
R 11 is selected from H, C 1-4 alkyl, (CHR) q OH, (CHR) q SH, (CHR) q OR 11d , (CHR) q S(O) p R 11d , (CHR) r C(O)R 11b , (CHR) r NR 11a R 11a , (CHR) r C(O)NR 11a R 11a , (CHR) r C(O)R 11a OR 11d , (CHR) q NR 11a C(O)R 11b , (CHR) q NR 11a C(O)OR 11d , (CHR) q OC(O)NR 11a R 11a , (CHR) r C(O)OR 11d , a (CHR) r —C 3-6 carbocyclic residue substituted with 0–5 R 11e , and a (CHR) r -5–10 membered heterocyclic system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–3 R 11e ;
R 11a , at each occurrence, is independently selected from H, C 1-4 alkyl, C 3-4 alkenyl, C 3-4 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, a (CH 2 ) r C 3-6 carbocyclic residue substituted with 0–5 R 11e , and a (CH 2 ) r -5–6 membered heterocyclic system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–3 R 11e ;
R 11b , at each occurrence, is independently selected from C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, a (CH 2 ) r —C 3-6 carbocyclic residue substituted with 0–2 R 11e , and a (CH 2 ) r -5–6 membered heterocyclic system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–3 R 11e ;
R 11d , at each occurrence, is independently selected from H, methyl, —CF 3 , C 2-4 alkyl, C 3-6 alkenyl, C 3-6 alkynyl, a C 3-6 carbocyclic residue substituted with 0–3 R 11e , and a (CH 2 ) r -5–6 membered heterocyclic system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–3 R 11e ;
R 11e , at each occurrence, is selected from C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 3-6 cycloalkyl, Cl, F, Br, I, CN, NO 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC 1-5 alkyl, OH, —O—C 1-6 alkyl, SH, (CH 2 ) r SC 1-5 alkyl, (CH 2 ) r NR 11f R 11f , and (CH 2 ) r phenyl;
R 11f , at each occurrence, is selected from H, C 1-6 alkyl, and C 3-6 cycloalkyl;
R 12 is selected from H, C 1-4 alkyl, (CHR) q OH, (CHR) q SH, (CHR) q OR 12d , (CHR) q S(O) p R 12d , (CHR) r C(O)R 12b , (CHR) r NR 12a R 12a , (CHR) r C(O)NR 12a R 12a , (CHR) r C(O)NR 12a OR 12d , (CHR) q NR 12a C(O)R 12b , (CHR) q NR 12a C(O)OR 12d , (CHR) q OC(O)NR 12a R 12a , (CHR) r C(O)OR 12d , a (CHR) r —C 3-6 carbocyclic residue substituted with 0–5 R 12e , and a (CHR) r -5–10 membered heterocyclic system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–3 R 12e ;
R 12a , at each occurrence, is independently selected from H, C 1-4 alkyl, C 3-4 alkenyl, C 3-4 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, a (CH 2 ) r —C 3-6 carbocyclic residue substituted with 0–5 R 12e , and a (CH 2 ) r -5–6 membered heterocyclic system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–3 R 12e ;
R 12b , at each occurrence, is independently selected from C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, a (CH 2 ) r C 3-6 carbocyclic residue substituted with 0–2 R 12e , and a (CH 2 ) r -5–6 membered heterocyclic system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–3 R 12e ;
R 12d , at each occurrence, is independently selected from H, methyl, —CF 3 , C 2-4 alkyl, C 3-6 alkenyl, C 3-6 alkynyl, a C 3-6 carbocyclic residue substituted with 0–3 R 12e , and a (CH 2 ) r -5–6 membered heterocyclic system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–3 R 12e ;
R 12e , at each occurrence, is selected from C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 3-6 cycloalkyl, Cl, F, Br, I, CN, NO 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC 1-5 alkyl, OH, —O—C 1-6 alkyl, SH, (CH 2 ) r SC 1-5 alkyl, (CH 2 ) r NR 12f R 12f , and (CH 2 ) r phenyl;
R 12f , at each occurrence, is selected from H, C 1-6 alkyl, and C 3-6 cycloalkyl;
R 13 , at each occurrence, is independently selected from H, and C 1-4 alkyl substituted with 0–1 R 13b , —OH, —NH 2 , F, Cl, Br, I, —OR 13a , —N(R 13a ) 2 , and C 1-4 alkyl substituted with 0–3 R 13b ;
R 13a is selected from H, C 1-4 alkyl and C 3-6 cycloalkyl;
R 13b , at each occurrence, is independently selected from —OH, —SH, —NR 13c R 13c , —C(O)NR 13c R 13c , and —NHC(O)R 13c ;
R 13c is selected from H, C 1-4 alkyl and C 3-6 cycloalkyl;
l is selected from 1, 2 and 3;
n is 1;
m is selected from 0 and 1;
p, at each occurrence, is independently selected from 0, 1, and 2;
q, at each occurrence, is independently selected from 1, 2, 3, and 4;
r, at each occurrence, is independently selected from 0, 1, 2, 3, and 4;
t, at each occurrence, is independently selected from 2, 3, and 4;
s is selected from 0 and 1.
2. A compound of claim 1 , wherein the compound is of formula (I):
or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein:
ring B is a cyclohexyl group; ring B being substituted with 0–2 R 5 ;
X is selected from O or S;
Z is —NR 9 —; wherein neither Z nor R 13 are connected to a carbon atom labeled (b);
bond (a) is a single bond;
E is selected from —S(O) p CHR e —, —CHR e NR e —, —C(O)—NR e —, —NR e C(O)NR e —, —SO 2 —NR e —, and —NR e SO 2 NR e —;
R e is independently selected from H and C 1-3 alkyl;
R 1 is selected from a C 6–10 aryl group substituted with 0–5 R 6 ;
R 2 is selected from a 5–10 membered heteroaryl system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–3 R 7 ;
R 5 , at each occurrence, is independently selected from H, ═O, C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CRR) r OH, (CRR) r SH, (CRR) r OR 5d , (CHR) r SR 5d , (CRR) r NR 5a R 5a , (CRR) r C(O)OH, (CRR) r C(O)R 5b , (CRR) r C(O)NR 5a R 5a , (CRR) r NR 5a C(O)R 5b , (CRR) r OC(O)NR 5a R 5a , (CRR) r NR 5a C(O)OR 5d , (CRR) r NR 5a C(O)NR 5a R 5a , (CRR) r NR 5a C(O)H, (CRR) r C(O)OR 5d , (CRR) r OC(O)R 5b , (CRR) r S(O) p R 5b , (CRR) r S(O) 2 NR 5a R 5a , (CRR) r NR 5a S(O) 2 R 5b , (CRR) r NR 5a S(O) 2 NR 5a R 5a , C 1-6 haloalkyl, a (CRR) r —C 3-10 carbocyclic residue substituted with 0–3 R 5c , and a (CRR) r -5–10 membered heterocyclic system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–2 R 5c ;
R 5a , at each occurrence, is independently selected from H, methyl substituted with 0–1 R 5g , C 2-6 alkyl substituted with 0–2 R 5e , C 3-8 alkenyl substituted with 0–2 R 5e , C 3-8 alkynyl substituted with 0–2 R 5e , a (CH 2 ) r —C 3-10 carbocyclic residue substituted with 0–5 R 5e , and a (CH 2 ) r -5–10 membered heterocyclic system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–3 R 5e ;
R 5b , at each occurrence, is selected from C 1-6 alkyl substituted with 0–3 R 5e , C 3-8 alkenyl substituted with 0–2 R 5e , C 3-8 alkynyl substituted with 0–2 R 5e , a (CH 2 ) r C 3-6 carbocyclic residue substituted with 0–2 R 5e , and a (CH 2 ) r -5–6 membered heterocyclic system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–3 R 5e ;
R 5c , at each occurrence, is selected from C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, Cl, Br, I, F, (CF 2 ) r CF 3 , NO 2 , CN, (CH 2 ) r NR 5f R 5f , (CH 2 ) r OH, (CH 2 ) r OC 1-4 alkyl, (CH 2 ) r SC 1-4 alkyl, (CH 2 ) r C(O)OH, (CH 2 ) r (CO)R 5b , (CH 2 ) r C(O)NR 5f R 5f , (CH 2 ) r OC(O)NR 5f R 5f , (CH 2 ) r NR 5f C(O)R 5b , (CH 2 ) r C(O)OC 1-4 alkyl, (CH 2 ) r NR 5f C(O)OC 1-4 alkyl, (CH 2 ) r OC(O)R 5b , (CH 2 ) r C(═NR 5f )NR 5f R 5f , (CH 2 ) r S(O) p R 5b , (CH 2 ) r NHC(═NR 5f )NR 5f R 5f , (CH 2 ) r S(O) 2 NR 5f R 5f , (CH 2 ) r NR 5f S(O) 2 R 5b , and (CH 2 ) r phenyl substituted with 0–3 R 5e ;
R 5d , at each occurrence, is selected from methyl, CF 3 , C 2-6 alkyl substituted with 0–2 R 5e , C 3-8 alkenyl substituted with 0–2 R 5e , C 3-8 alkynyl substituted with 0–2 R 5e , and a C 3-10 carbocyclic residue substituted with 0–3 R 5e ;
R 5e , at each occurrence, is selected from C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 3-6 cycloalkyl, Cl, F, Br, I, CN, NO 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC 1-5 alkyl, OH, SH, (CH 2 ) r SC 1-5 alkyl, (CH 2 ) r NR 5f R 5f , and (CH 2 ) r phenyl;
R 5f , at each occurrence, is selected from H, C 1-6 alkyl, and C 3-6 cycloalkyl;
R 5g is independently selected from —C(O)R 5b , —C(O)OR 5d , —C(O)NR 5f R 5f , and (CH 2 ) r phenyl;
R, at each occurrence, is selected from H, C 1-6 alkyl substituted with R 5e , C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, and (CH 2 ) r phenyl substituted with R 5e ;
R 6 , at each occurrence, is selected from C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, Cl, Br, I, F, NO 2 , CN, (CR′R′) r NR 6a R 6a , (CR′R′) r OH, (CR′R′) r O(CR′R′) r R 6d , (CR′R′) r SH, (CR′R′) r C(O)H, (CR′R′) r S(CR′R′) r R 6d , (CR′R′) r SC(O)(CR′R′) r R 6b , (CR′R′) r C(O)OH, (CR′R′) r C(O)(CR′R′) r R 6b , (CR′R′) r NR 6a R 6a , (CR′R′) r C(O)NR 6a R 6a , (CR′R′) r NR 6f C(O)(CR′R′) r R 6b , (CR′R′) r C(O)O(CR′R′) r R 6d , (CR′R′) r OC(O)(CR′R′) r R 6b , (CR′R′) r OC(O)NR 6a (CR′R′) r R 6a , (CR′R′) r NR 6a C(O)NR 6a (CR′R′) r R 6d , (CR′R′) r NR 6a C(S)NR 6a (CR′R′) r R 6d , (CR′R′) r NR 6a C(O)O(CR′R′) r R 6b , (CR′R′) r C(═NR 6f )NR 6a R 6a , (CR′R′) r NHC(═NR 6f )NR 6f R 6f , (CR′R′) r S(O) p (CR′R′) r R 6b , (CR′R′) r S(O) 2 NR 6a R 6a , (CR′R′) r NR 6f S(O) 2 NR 6a R 6a , (CR′R′) r NR 6f S(O) 2 (CR′R′) r R 6b , C 1-6 haloalkyl, C 2-8 alkenyl substituted with 0–3 R′, C 2-8 alkynyl substituted with 0–3 R′, (CR′R′) r phenyl substituted with 0–3 R 6e , and a (CH z ) r -5–6 membered heterocyclic system containing 1–2 heteroatoms selected from N, O, and S, substituted with 0–2 R 6e ;
alternatively, two R 6 on adjacent atoms on R 1 may join to form a cyclic acetal;
R 6a , at each occurrence, is selected from H, methyl substituted with 0–1 R 6g ′, C 2-6 alkyl substituted with 0–2 R 6e , C 3-8 alkenyl substituted with 0–2 R 6e , C 3-8 alkynyl substituted with 0–2 R 6e , a (CH 2 ) r C 3-10 carbocyclic residue substituted with 0–5 R 6e , and a (CH 2 ) r -5–10 membered heterocyclic system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–2 R 6e ;
R 6b , at each occurrence, is selected from H, C 1-6 alkyl substituted with 0–2 R 6e , C 3-8 alkenyl substituted with 0–2 R 6e , C 3-8 alkynyl substituted with 0–2 R 6e , a (CH 2 ) r C 3-6 carbocyclic residue substituted with 0–3 R 6e , and a (CH 2 ) r -5–6 membered heterocyclic system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–2 R 6e ;
R 6d , at each occurrence, is selected from C 3-8 alkenyl substituted with 0–2 R 6e , C 3-8 alkynyl substituted with 0–2 R 6e , methyl, CF 3 , C 2-6 alkyl substituted with 0–3 R 6e , C 2-4 haloalkyl, a (CH 2 ) r —C 3-10 carbocyclic residue substituted with 0–3 R 6e , and a (CH 2 ) r -5–6 membered heterocyclic system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–3 R 6e ;
R 6e , at each occurrence, is selected from C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, Cl, F, Br, I, CN, NO 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC 1-5 alkyl, OH, SH, (CH 2 ) r SC 1-5 alkyl, (CH 2 ) r NR 6f R 6f , and (CH 2 ) r phenyl;
R 6f , at each occurrence, is selected from H, C 1-5 alkyl, and C 3-6 cycloalkyl, and phenyl;
R 6g is independently selected from —C(O)R 6b , —C(O)OR 6d , —C(O)NR 6f R 6f , and (CH 2 ) r phenyl;
R 7 , at each occurrence, is selected from C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, Cl, Br, I, F, NO 2 , CN, (CR′R′) r NR 7a R 7a , (CR′R′) r OH, (CR′R′) r O(CR′R′) r R 7d , (CR′R′) r SH, (CR′R′) r C(O)H, (CR′R′) r S(CR′R′) r R 7d , (CR′R′) r C(O)OH, (CR′R′) r C(O)(CR′R′) r R 7b , (CR′R′) r C(O)NR 7a R 7a , (CR′R′) r NR 7e C(O)(CR′R′) r R 7b , (CR′R′) r C(O)O(CR′R′) r R 7d , (CR′R′) r OC(O)(CR′R′) r R 7b , (CR′R′) r OC(O)NR 7a (CR′R′) r R 7a , (CR′R′) r NR 7a C(O)NR 7a (CR′R′) r R 7a , (CR′R′) r NR 7f C(O)O(CR′R′) r R 7d , (CR′R′) r C(═NR 7f )NR 7a R 7a , (CR′R′) r NHC(═NR 7f )NR 7f R 7f , (CR′R′) r S(O) p (CR′R′) r R 7b , (CR′R′) r S(O) 2 NR 7a R 7a , (CR′R′) r NR 7a S(O) 2 NR 7a R 7a , (CR′R′) r NR 7f S(O) 2 (CR′R′) r R 7b , C 1-6 haloalkyl, C 2-8 alkenyl substituted with 0–3 R′, C 2-8 alkynyl substituted with 0–3 R′, and (CR′R′) r phenyl substituted with 0–3 R 7e ;
alternatively, two R 7 on adjacent atoms on R 2 may join to form a cyclic acetal;
R 7e , at each occurrence, is independently selected from H, methyl substituted with 0–1 R 7g , C 2-6 alkyl substituted with 0–2 R 7e , C 3-8 alkenyl substituted with 0–2 R 7e , C 3-8 alkynyl substituted with 0–2 R 7e , a (CH 2 ) r —C 3-10 carbocyclic residue substituted with 0–5 R 7e , and a (CH 2 ) r -5–10 membered heterocyclic system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–2 R 7e ;
R 7b , at each occurrence, is selected from C 1-6 alkyl substituted with 0–2 R 7e , C 3-8 alkenyl substituted with 0–2 R 7e , C 3-8 alkynyl substituted with 0–2 R 7e , a (CH 2 ) r C 3-6 carbocyclic residue substituted with 0–3 R 7e , and a (CH 2 ) r -5–6 membered heterocyclic system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–2 R 7e ;
R 7d , at each occurrence, is selected from C 3-8 alkenyl substituted with 0–2 R 7e , C 3-8 alkynyl substituted with 0–2 R 7e , methyl, CF 3 , C 2-4 haloalkyl, C 2-6 alkyl substituted with 0–3 R 7e , a (CH 2 ) r —C 3-10 carbocyclic residue substituted with 0–3 R 7e , and a (CH 2 ) r -5–6 membered heterocyclic system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–3 R 7e ;
R 7e , at each occurrence, is selected from C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, Cl, F, Br, I, ON, NO 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC 1-5 alkyl, OH, SH, C(O)OC 1-5 alkyl, (CH 2 ) r SC 1-5 alkyl, (CH 2 ) r NR 7f R 7f , and (CH 2 ) r phenyl;
R 7f , at each occurrence, is selected from H, C 1-5 alkyl, and C 3-6 cycloalkyl, and phenyl;
R 7g is independently selected from —C(O)R 7b , —C(O)OR 7d , —C(O)NR 7f R 7f , and (CH 2 ) r phenyl;
R′, at each occurrence, is selected from H, C 1-6 alkyl substituted with R 6e , C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, and (CH 2 ) r phenyl substituted with R 6e ;
R 9 is selected from H, C 1-4 alkyl, C 3-4 cycloalkyl, —C(O)H, and —C(O)—C 1-4 alkyl;
R 10 is independently selected from H, and C 1-4 alkyl substituted with 0–1 R 10b ;
R 10b , at each occurrence, is independently selected from —OH, —SH, —NR 10c R 10c , —C(O)NR 10c R 10c , and —NHC(O)R 10c ;
R 10c is selected from H, C 1-4 alkyl and C 3-6 cycloalkyl;
R 11 is selected from H, C 2-4 alkyl, (CHR) q OH, (CHR) q SH, (CHR) q OR 11d , (CHR) q S(O) p R 11d , (CHR) r C(O)R 11b , (CHR) r NR 11a R 11a , (CHR) r C(O)NR 11a R 11a , (CHR) r C(O)NR 11a OR 11d , (CHR) q NR 11a C(O)R 11b , (CHR) q NR 11a C(O)OR 11d , (CHR) q OC(O)NR 11a R 11a , (CHR) r C(O)OR 11d , a (CHR) r —C 3-6 carbocyclic residue substituted with 0–5 R 11e , and a (CHR) r -5–10 membered heterocyclic system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–3 R 11e ;
R 11a , at each occurrence, is independently selected from H, C 2-4 alkyl, C 3-4 alkenyl, C 3-4 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, a (CH 2 ) r –C 3-6 carbocyclic residue substituted with 0–5 R 11e , and a (CH 2 ) r -5–6 membered heterocyclic system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–3 R 11e ;
R 11b , at each occurrence, is independently selected from 01–4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, a (CH 2 ) r —C 3-6 carbocyclic residue substituted with 0–2 R 11e , and a (CH 2 ) r -5–6 membered heterocyclic system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–3 R 11e ;
R 11d , at each occurrence, is independently selected from H, methyl, —CF 3 m C 2-4 alkyl, C 3-6 alkenyl, C 3-6 alkynyl, a C 3-6 carbocyclic residue substituted with 0–3 R 11e , and a (CH 2 ) r -5–6 membered heterocyclic system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–3 R 11e ;
R 11e , at each occurrence, is selected from C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 3-6 cycloalkyl, Cl, F, Br, I, ON, NO 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC 1-5 alkyl, OH, —O—C 1-6 alkyl, SH, (CH 2 ) r SC 1-5 alkyl, (CH 2 ) r NR 11f R 11f , and (CH 2 ) r phenyl;
R 11f , at each occurrence, is selected from H, C 1-6 alkyl, and C 3-6 cycloalkyl;
R 12 is selected from H, C 1-4 alkyl, (CHR) q OH, (CHR) q SH, (CHR) q OR 12d , (CHR) q S(O) p R 12d , (CHR) r C(O)R 12b , (CHR) r NR 12a R 12a , (CHR) r C(O)NR 12a R 12a , (CHR) r C(O)NR 12a OR 12d , (CHR) q NR 12a C(O)R 12b , (CHR) q NH 12a C(O)OR 12d , (CHR) q OC(O)NR 12a R 12a , (CHR) r C(O)OR 12d , a (CHR) r —C 3-6 carbocyclic residue substituted with 0–5 R 12e , and a (CHR) r -5–10 membered heterocyclic system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–3 R 12e ;
R 12a , at each occurrence, is independently selected from H, C 1-4 alkyl, C 3-4 alkenyl, C 3-4 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, a (CH 2 ) r –C 3-6 carbocyclic residue substituted with 0–5 R 12e , and a (CH 2 ) r -5–6 membered heterocyclic system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–3 R 12e ;
R 12b , at each occurrence, is independently selected from C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, a (CH 2 ) r —C 3-6 carbocyclic residue substituted with 0–2 R 12e , and a (CH 2 ) r -5–6 membered heterocyclic system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–3 R 12e ;
R 12d , at each occurrence, is independently selected from H, methyl, —CF 3 , C 2-4 alkyl, C 3-6 alkenyl, C 3-6 alkynyl, a C 3-6 carbocyclic residue substituted with 0–3 R 12e , and a (CH 2 ) r -5–6 membered heterocyclic system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–3 R 12e ;
R 12e , at each occurrence, is selected from C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 3-6 cycloalkyl, Cl, F, Br, I, CN, NO 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC 1-5 alkyl, OH, —O—C 1-6 alkyl, SH, (CH 2 ) r SC 1-5 alkyl, (CH 2 ) r NR 12f R 12f , and (CH 2 ) r phenyl;
R 12f , at each occurrence, is selected from H, C 1-6 alkyl, and C 3-6 cycloalkyl;
R 13 , at each occurrence, is independently selected from H, and C 1-4 alkyl substituted with 0–1 R 13b , —OH, —NH 2 , F, Cl, Br, I, —OR 13a , —N(R 13a ) 2 , and C 1-4 alkyl substituted with 0–3 R 13b ;
R 13a is selected from H, C 1-4 alkyl and C 3-6 cycloalkyl;
R 13b , at each occurrence, is independently selected from —OH, —SH, —NR 13c R 13c , —C(O)NR 13c R 13c , and —NHC(O)R 13c ;
R 13c is selected from H, C 1-4 alkyl and C 3-6 cycloalkyl;
l is selected from 1, 2 and 3;
n is 1;
m is selected from 0 and 1;
p, at each occurrence, is independently selected from 0, 1, and 2;
q, at each occurrence, is independently selected from 1, 2, 3, and 4;
r, at each occurrence, is independently selected from 0, 1, 2, 3, and 4;
t, at each occurrence, is independently selected from 2, 3, and 4;
s is selected from 0 and 1.
3. The compound of claim 2 , wherein
m is 0.
4. The compound of claim 3 , wherein:
ring B is
ring B being optionally substituted with 0–1 R 5 ; and
R 11 and R 12 are H.
5. The compounds of claim 4 , wherein:
R 5 , at each occurrence, is independently selected from H, C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CRR) r OH, (CRR) r SH, (CRR) r OR 5d , (CRR) r SR 5d , (CRR) r NR 5a R 5a , (CRR) r C(O)OH, (CRR) r C(O)R 5b , (CRR) r C(O)NR 5a R 5a , (CRR) r NR 5a C(O)R 5b , (CRR) r NR 5a C(O)OR 5d , (CRR) r OC(O)NR 5a R 5a , (CHR) r NR 5a C(O)NR 5a R 5a , CRR(CRR) r NR 5a C(O)H, (CRR) r C(O)OR 5b , (CRR) r OC(O)R 5b , (CRR) r S(O) p R 5b , (CRR) r S(O) 2 NR 5a R 5a , (CRR) r NR 5a S(O) 2 R 5b , and C 1-6 haloalkyl;
R 5a , at each occurrence, is independently selected from H, methyl, C 1-6 alkyl substituted with 0–2 R 5e wherein the alkyl is selected from ethyl, propyl, i-propyl, butyl, i-butyl, pentyl, hexyl, C 3 alkenyl, substituted with 0–1 R 5e , wherein the alkenyl is selected from allyl, C 3 alkynyl substituted with 0–1 R 5e wherein the alkynyl is selected from propynyl, and a (CH 2 ) r —C 3-4 carbocyclic residue substituted with 0–5 R 5e , wherein the carbocyclic residue is selected from cyclopropyl, and cyclobutyl;
R 5b , at each occurrence, is selected from C 1-6 alkyl substituted with 0–2 R 5e , wherein the alkyl is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, pentyl, and hexyl, a (CH 2 ) r —C 3-4 carbocyclic residue substituted with 0–2 R 5e , wherein the carbocyclic residue is selected from cyclopropyl, and cyclobutyl; and
R 5d , at each occurrence, is selected from methyl, CF 3 , C 2-6 alkyl substituted with 0–2 R 5e , wherein the alkyl is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, pentyl, and hexyl, C 3-8 alkenyl, C 3-8 alkynyl, and a C 3-10 carbocyclic residue substituted with 0–3 R 5e .
6. The compound of claim 5 , wherein:
R, at each occurrence, is independently selected from H, methyl, ethyl, propyl, allyl, propynyl, (CH 2 ) r C 3-6 cycloalkyl, and (CH 2 ) r phenyl substituted with R 6e ;
R 5 , at each occurrence, is independently selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, allyl, propynyl, (CH 2 ) r OH, (CH 2 ) r OR 5d , (CH 2 ) r NR 5a R 5a , (CH 2 ) r C(O)OH, (CH 2 ) r C(O)R 5b , (CH 2 ) r C(O)NR 5a R 5a , (CH 2 ) r NR 5a C(O)R 5b , (CH 2 ) r OC(O)NR 5a R 5a , (CH 2 ) r NR 5a C(O)OR 5d , (CH 2 ) r NR 5a C(O)R 5b , (CH 2 ) r C(O)OR 5b , (CH 2 ) r OC(O)R 5b , (CH 2 ) r NR 5a C(O)R 5b , and C 1-6 haloalkyl;
R 5a , at each occurrence, is independently selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, pentyl, hexyl, cyclopropyl, and cyclobutyl; and
r, at each occurrence, is selected from 0, 1, and 2.
7. The compound of claim 6 , wherein:
R 1 is selected from phenyl substituted with 0–2 R 6 , naphthyl substituted with 0–2 R 6 ,
R 2 is selected from a 5–10 membered heteroaryl system containing 1–4 heteroatoms selected from N, O, and S, substituted with 0–3 R 7 wherein the heteroaryl is selected from indolyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzoxazolyl, benzthiazolyl, benzo[b]thiophene, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl, cinnolinyl, furanyl, imidazolyl, indazolyl, indolyl, isoquinolinyl isothiazolyl, isoxazolyl, oxazolyl, phthalazinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrido[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, pyridinyl, pyrimidinyl, pyrrolyl, pyrrolo[2,1-f][1,2,4]triazine, quinazolinyl, quinolinyl, thiazolyl, thienyl, and tetrazolyl.
8. The compound of claim 7 , wherein:
R 6 , at each occurrence, is selected from C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CR′R′) r C 3-6 cycloalkyl, Cl, Br, I, F, NO 2 , CN, (CR′R′) r NR 6a R 6a , (CR′R′) r OH, (CR′R′) r O(CR′R′) r R 6d , (CR′R′) r SH, (CR′R′) r C(O)H, (CR′R′) r S(CR′R′) r R 6d , (CR′R′) r C(O)OH, (CR′R′) r C(O)(CR′R′) r R 6b , (CR′R′) r C(O)NR 6a R 6a , (CR′R′) r NR 6f C(O)(CR′R′) r R 6b , (CR′R′) r C(O)O(CR′R′) r R 6d , (CR′R′) r NR 6a C(O)NR 6a R 6a , (CR′R′) r NR 6a C(S)NR 6a R 6a , (CR′R′) r OC(O)(CR′R′) r R 5b , (CR′R′) r S(O) p (CR′R′) r R 6b , (CR′R′) r S(O) 2 NR 6a R 6a , (CR′R′) r NR 6f S(O) 2 (CR′R′) r R 6b , (CR′R′) r NR 6f S(O) 2 NR 6a R 6a , C 1-6 haloalkyl, and (CR′R′) r phenyl substituted with 0–3 R 6e , and a (CH 2 ) r -5–6membered heterocyclic system containing 1–2 heteroatoms selected from N, O, and S, substituted with 0–2 R 6e ;
R 6a , at each occurrence, is independently selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, cyclopropyl and phenyl;
R 6b , at each occurrence, is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, cyclopropyl, and phenyl;
R 6d , at each occurrence, is selected from methyl, CF 3 , ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, cyclopropyl, and phenyl;
R 6e , at each occurrence, is selected from C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, Cl, F, Br, I, CN, NO 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC 1-5 alkyl, OH, SH, (CH 2 ) r SC 1-5 alkyl, (CH 2 ) r NR 6f R 6f , and (CH 2 ) r phenyl;
R 6f , at each occurrence, is selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, cyclopropyl, and phenyl;
R 7 is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, s-butyl, t-butyl, pentyl, hexyl, (CR′R′) r C 3-6 cycloalkyl, Cl, Br, I, F, NO 2 , CN, (CR′R′) r NR 7a R 7a , (CR′R′) r OH, (CR′R′) r O(CH) r R 7d , (CR′R′) r SH, (CR′R′) r C(O)H, (CR′R′) r S(CR′R′) r R 7d , (CR′R′) r C(O)OH, (CR′R′) r C(O)(CR′R′) r R 7b , (CR′R′) r C(O)NR 7a R 7a , (CR′R′) r NR 7f C(O)(CR′R′) r R 7b , (CR′R′) r C(O)O(CR′R′) r R 7d , (CR′R′) r OC(O)(CR′R′) r R 7b , (CR′R′) r NR 7a C(O)NR 7a R 7a , (CR′R′) r NR 7a C(O)O(CR′R′) r R 7d , (CR′R′) r S(O) p (CR′R′) r R 7b , (CR′R′) r S(O) 2 NR 7a R 7a , (CR′R′) r NR 7f S(O) 2 (CR′R′) r R 7b , C 1-6 haloalkyl, and (CR′R′) r phenyl substituted with 0–3 R 7e ;
R 7a , at each occurrence, is selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, prop-2-enyl, 2-methyl-2-propenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, CH 2 cyclopropyl, and benzyl;
R 7b , at each occurrence, is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, cyclopropyl, cyclopentyl, CH 2 -cyclopentyl, cyclohexyl, CH 2 -cyclohexyl, CF 3 , pyrrolidinyl, morpholinyl, piperizenyl substituted with 0–1 R 7e , and azetidinyl;
R 7d , at each occurrence, is selected from methyl, CF 3 , CF 2 CF 3 , CHF 2 , CH 2 F, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, and cyclopropyl;
R 7e , at each occurrence, is selected from C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, Cl, F, Br, I, ON, NO 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC 1-5 alkyl, OH, SH, C(O)OC 1-5 alkyl, (CH 2 ) r SC 1-5 alkyl, (CH 2 ) r NR 7f R 7f , and (CH 2 ) r phenyl;
R 7f , at each occurrence, is selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, cyclopropyl, and phenyl; and
r is 0 or 1.
9. The compound of claim 8 , wherein:
R 7 is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, s-butyl, pentyl, hexyl, Cl, Br, I, F, ON, NO 2 , NR 7a R 7a , NHC(O)NHR 7a , NR 7a C(O)R 7b , NR 7a C(O)OR 7d , CF 3 , CF 2 CF 3 , CHF 2 , CH 2 F, OCF 3 , C(O)R 7b , C(O)OR 7d , NR 7f C(O)NR 7a R 7a , NHS(O) 2 R 7b ,
10. The compound of claim 9 , wherein:
ring B is
ring B being optionally substituted with 0–1 R 5 ;
R 1 is selected from a C 6-10 aryl group substituted with 0–3 R 6 wherein the aryl group is selected from phenyl and naphthyl,
R 6 is selected from methyl, ethyl, propyl, i-propyl, butyl, F, Cl, Br, I, NO 2 , CN, O(CH 2 ) r R 6d , C(O)H, C(O)R 6d , C(O)OH, SR 6d , NR 6a R 6a , NC(O)R 6b , OC(O)R 6b , S(O) p R 6b , (CHR′) r S(O) 2 NR 6a R 6a , and CF 3 ;
R 6a is H, methyl, or ethyl;
R 6b is H, methyl, ethyl, propyl, i-propyl or butyl;
R 6d is methyl, phenyl, CF 3 and (CH 2 )-phenyl; and
r is 0 or 1.
11. The compound of claim 10 , wherein:
ring B is
ring B being substituted with 0–1 R 5 ;
R 1 is selected from a C 6-10 aryl group substituted with 0–3 R 6 wherein the aryl group is selected from phenyl;
R 4 is selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, allyl and (CH 2 ) r C(O)R 4b ;
R 5 is selected from H, OH, OCH 3 , and NR 5a R 5a ;
R 5a is selected from H, methyl, ethyl, propyl, i-propyl, butyl, s-butyl, i-butyl, t-butyl, pentyl, hexyl, allyl, propargyl, cyclopropyl, cyclopropylmethyl, acetyl, methysulfonyl, —C(O)CF 3 , C(═N)NH 2 , benzyl, and —C(O)O-t-butyl;
R 6 is selected from methyl, ethyl, propyl, i-propyl, butyl, vinyl, F, Cl, Br, I, CN, NR 6a R 6a , C(O)H, C(O)OH, C(O)R 6b , SR 6d , S(O) p R 6d , S(O) 2 NR 6a R 6a , CF 3 , and CH 2 OH;
R 6b is H, methyl, ethyl, propyl, i-propyl or butyl;
R 6d is methyl;
R 7 is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, s-butyl, pentyl, hexyl, Cl, Br, I, F, CN, NO 2 , NR 7a R 7a , NHC(O)NHR 7a , NR 7a C(O)R 7b , NR 7a C(O)OR 7d , CF 3 , CF 2 CF 3 , CHF 2 , CH 2 F, OCF 3 , OCF 2 CF 3 , OCHF 2 , and OCH 2 F, C(O)OR 7d , C(O)R 7b , NR 7b C(O)NR 7a R 7a , NHS(O) 2 R 7b ,
R 7a is selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, neo-pentyl, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl;
R 7b is selected from cyclohexyl and CF 3 ; and
R 7d is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, and t-butyl.
12. The compound of claim 11 , wherein:
ring B is selected from
ring B being substituted with 0–1 R 5 ;
R 1 is selected from a C 6-10 aryl group substituted with 0–3 R 6 wherein the aryl group is phenyl;
R 6 is selected from methyl, ethyl, propyl, i-propyl, F, Cl, Br, CN, SCH 3 , and CF 3 ;
R 7 is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, s-butyl, t-butyl, pentyl, hexyl, phenyl, adamantyl, benzyl, Cl, Br, I, F, ON, NO 2 , NR 7a R 7a , OR 7d , NHC(O)NHR 7a , NR 7a C(O)R 7b , NR 7a C(O)OR 7d , CF 3 , CF 2 CF 3 , CHF 2 , CH 2 F, OCF 3 , OCF 2 CF 3 , OCHF 2 , and OCH 2 F, C(O)OR 7d , C(O)R 7b , and NR 7f C(O)NR 7a R 7a ;
R 7a is selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, neo-pentyl, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
13. The compound of claim 12 , wherein
E is selected from —CH 2 —NH—, —C(O)—NH— and —SO 2 —CH 2 —.
14. The compound of claim 1 , wherein
B is
ring B being substituted with 0–1 R 5 ; and
R 5 is selected from H, N(→O)R 5a R 5a , N 3 , NR 5a C(O)R 5b , NR 5a C(O)H, NR 5a C(O)OR 5d , NR 5a C(O)NR 5a R 5a , and NR 5a R 5a , and a (CH 2 ) r -5–6 membered heterocyclic system containing 1–2 heteroatoms selected from N, O, and S, substituted with 0–2 R 5e , wherein the heterocyclic system is selected from pyrrolidinyl, piperidinyl, pyrrolidin-2-one, and isothiazolidine 1,1-dioxide.
15. The compound of claim 12 , wherein
R 6 is selected from methyl, ethyl, propyl, i-propyl, butyl, vinyl, F, Cl, Br, I, C(O)H, C(O)R 6b , SR 6d , S(O) p R 6d , CF 3 , and CH 2 OH;
R 6b is H, methyl, ethyl, propyl, i-propyl or butyl;
R 6d is methyl;
R 7 is selected from Cl, Br, NR 7a R 7a , NR 7a C(O)OR 7d , NHC(O)NHR 7a , OCF 3 , and CF 3 ;
R 7a is selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pantyl, neo-pentyl, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl;
R 7d is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, and t-butyl.
16. The compound of claim 1 , wherein the compound is of formula (Ia) or (Ic)
17. The compound of claim 1 , wherein the compound is of formula (I) is selected:
3-(Benzo[b]thiophen-3-ylamino)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-(phenylsulfonylmethyl)cyclohexyl)pyrrolidin-2-one;
(S)-3-(6-chloroquinazolin-4-ylamino)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-(phenylsulfonylmethyl)cyclohexyl)pyrrolidin-2-one;
(S)-3-(6,8-dichloroquinazolin-4-ylamino)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-(phenylsulfonylmethyl)cyclohexyl)pyrrolidin-2-one;
3-((E)-3(R*)-(trifluoromethyl)styryl)-1-((1S*,2R*,4R*)-4-(isopropyl(methyl)amino)-2-(phenylsulfonylmethyl)cyclohexyl)pyrrolidin-2-one;
(R)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-(phenylsulfonylmethyl)cyclohexyl)-3-(6-(trifluoromethyl)quinolin-4-ylamino)pyrrolidin-2-one;
(S)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-(phenylsulfonylmethyl)cyclohexyl)-3-(6-(trifluoromethyl)quinolin-4-ylamino)pyrrolidin-2-one;
(R)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-(phenylsulfonylmethyl)cyclohexyl)-3-(7-(trifluoromethyl)quinolin-4-ylamino)pyrrolidin-2-one;
(S)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-(phenylsulfonylmethyl)cyclohexyl)-3-(7-(trifluoromethyl)quinolin-4-ylamino)pyrrolidin-2-one;
1-[(1S,2R,4R)-2-Benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-chloro-2-trifluoromethyl-quinazolin-4-ylamino)-pyrrolidin-2-one;
1-[(1S,2R,4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(7-chloro-quinazolin-4-ylamino)-pyrrolidin-2-one;
1-[(1S,2R,4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(2,6-dichloro-quinazolin-4-ylamino)-pyrrolidin-2-one;
1-[(1S,2R,4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-chloro-2-dimethylamino-quinazolin-4-ylamino)-pyrrolidin-2-one;
1-[(1S,2R,4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-chloro-2-hydroxy-quinazolin-4-ylamino)-pyrrolidin-2-one;
1-[(1S,2R,4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-trifluoromethyl-quinazolin-4-ylamino)-pyrrolidin-2-one;
1-[(1S,2R,4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-tert-butyl-trieno[3,2-d]pyrimidin-4-ylamino)-pyrrolidin-2-one;
1-[(1S,2R,4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-tert-butyl-2-trifluoromethyl-thieno[3,2-d]pyrimidin-4-ylamino)-pyrrolidin-2-one;
1-[(1S,2R,4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-tert-butyl-pyrrolo[2,1-f][1,2,4]triazin-4-ylamino)-pyrrolidin-2-one;
(3S)-3-(6-Admantan-1-yl-pyrrolo[2,1-f][1,2,4]triazin-4-ylamino)-1-[(1S,2R,4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-pyrrolidin-2-one;
1-[(1S,2R,4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6,7-dimethoxy-quinazolin-4-ylamino)-pyrrolidin-2-one;
1-[(1S,2R,4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-fluoro-quinazolin-4-ylamino)-pyrrolidin-2-one;
1-[(1S,2R,4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-methyl-quinazolin-4-ylamino)-pyrrolidin-2-one;
1-[(1S,2R,4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-phenyl-thieno[2,3-d]pyrimidin-4-ylamino)-pyrrolidin-2-one;
1-[(1S,2R,4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-chloro-2-propyl-pyrido[2,3-d]pyrimidin-4-ylamino)-pyrrolidin-2-one;
1-[(1S,2R,4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-chloro-2-isopropyl-quinazolin-4-ylamino)-pyrrolidin-2-one;
1-[(1S,2R,4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(2-tert-butyl-6-chloro-quinazolin-4-ylamino)-pyrrolidin-2-one;
1-[(1S,2R,4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-chloro-2-methyl-quinazolin-4-ylamino)-pyrrolidin-2-one;
1-[(1S,2R,4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-chloro-2-ethyl-quinazolin-4-ylamino)-pyrrolidin-2-one;
1-[(1S,2R,4R)-2-Benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-tert-butyl-pyrimido[5,4-d]pyrimidin-4-ylamino)-pyrrolidin-2-one;
1-[(1S,2R,4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(pyrido[2,3-d]pyrimidin-4-ylamino)-pyrrolidin-2-one;
1-[(1S,2R,4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-chloro-pyrido[2,3-d]pyrimidin-4-ylamino)-pyrrolidin-2-one;
1-[(1S,2R,4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-chloro-2-trifluoromethyl-pyrido[2,3-d]pyrimidin-4-ylamino)-pyrrolidin-2-one;
1-[(1S,2R,4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-trifluoromethoxy-pyrrolo[2,3-d]pyrimidin-4-ylamino)-pyrrolidin-2-one;
1-[(1S,2R,4R)-2-benzenesulfonylmethyl-4-(isopropyl-methyl-amino)-cyclohexyl]-(3S)-3-(6-chloro-2-methylamino-quinazolin-4-ylamino)-pyrrolidin-2-one;
(3S)-3-(6-Fluoro-quinazolin-4-ylamino)-1-[(1S,2R,4R)-4-(isopropyl-methyl-amino)-2-(toluene-4-sulfonylmethyl)-cyclohexyl]-pyrrolidin-2-one;
(S)-3-(6-Bromoquinazolin-4-ylamino)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-(phenylsulfonylmethyl)cyclohexyl)pyrrolidin-2-one;
(S)-3-(6,7-Difluoroquinazolin-4-ylamino)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-(phenylsulfonylmethyl)cyclohexyl)pyrrolidin-2-one;
(S)-3-(6-Methoxyquinazolin-4-ylamino)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-(phenylsulfonylmethyl)cyolohexyl)pyrrolidin-2-one;
((S)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-(phenylsulfonylmethyl)cyclohexyl)-3-(quinazolin-4-ylamino)pyrrolidin-2-one;
(S)-3-(6-Iodoquinazolin-4-ylamino)-1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-(phenylsulfonylmethyl)cyclohexyl)pyrrolidin-2-one.
18. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1 .
19. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 7 .